Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients

Ding, Xi; Zhang, Jie; Liu, Di; Xu, Wen; Lu, De-yi; Zhang, Li-Ping; Su, Bo

doi:10.7150/jca.22656



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(5):792-796. doi:10.7150/jca.22656 This issue Cite

Research Paper

Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients

Xi Ding^1#, Jie Zhang^2#, Di Liu³, Wen Xu⁴, De-yi Lu⁵, Li-Ping Zhang^6✉, Bo Su^7✉

1. Department of General Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
2. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
3. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
4. Department of Respiratory Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
5. Department of Bioengineering, University of Illinois at Chicago
6. Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
7. Department of Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University
^# Equal contribution

Citation:

Ding X, Zhang J, Liu D, Xu W, Lu Dy, Zhang LP, Su B. Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. J Cancer 2018; 9(5):792-796. doi:10.7150/jca.22656. https://www.jcancer.org/v09p0792.htm

Other styles

Abstract

Cytokines are vital mediators involved in tumor immunity. We aimed to explore whether the expression levels of IL-1β, TNF-α and IL-6 have impacts on prognosis of SCLC patients. In this study, we concluded 707 non-operable SCLC patients at stage III or IV into this study and analyzed the relationships between interleukins and OS/PFS by cox regression analysis and Kaplan-Meier analysis (log-rank test). As a result, under current standard chemotherapy, SCLC patients with higher IL-6 expression level had a shortened OS compared with those with normal level (HR: 0.381, 95%CI: 0.177-0.822, p=0.014). Furthermore, IL-6 expression level contributed mostly to patients without a smoking history. Non-smoking patients with a high IL-6 level showed a 6 months shortened OS than those with normal IL-6 level (10.50 vs 16.90 months, p=0.003 by Log-Rank test in Kaplan-Meier analysis). IL-6 had no obvious impacts on first-line PFS in these SCLC patients. To conclude, IL-6 acts as an independent factor of long-term prognosis of SCLC patients under current therapy.

Keywords: small cell lung cancer, cytokine, IL-6, prognosis, tumor immunity

Citation styles

APA

Ding, X., Zhang, J., Liu, D., Xu, W., Lu, D.y., Zhang, L.P., Su, B. (2018). Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. Journal of Cancer, 9(5), 792-796. https://doi.org/10.7150/jca.22656.

ACS

Ding, X.; Zhang, J.; Liu, D.; Xu, W.; Lu, D.y.; Zhang, L.P.; Su, B. Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. J. Cancer 2018, 9 (5), 792-796. DOI: 10.7150/jca.22656.

NLM

CSE

Ding X, Zhang J, Liu D, Xu W, Lu Dy, Zhang LP, Su B. 2018. Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients. J Cancer. 9(5):792-796.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.